Study record

Central and peripheral mechanism of MOTS-c attenuates pain hypersensitivity in a mice model of inflammatory pain

Wang Z, Yang L, Xu L et al. · Neurol Res · 2024

AnimalMOTS-c administeredEvidence tier C

What this study reported

Reported that administered MOTS-c reduced pain-related behaviours in mice with formalin-, capsaicin-, carrageenan- and CFA-induced inflammatory pain. In the same mice, central MOTS-c was associated with lower spinal inflammatory factor release and less glial and neuronal activation, and peripheral MOTS-c with reduced inflammatory responses in hindpaw skin.

Limitations

Single mouse strain and males only; group sizes and blinding are not reported in the abstract; outcomes are reflex behaviours and marker expression rather than functional pain measures.

Study record

Annotated fields for this study
Study modelAnimal study (in vivo)
Substance studiedMOTS-c administeredSynthetic MOTS-c was given to cells, animals or people.
Speciesmouse
System studiedMale Kunming mice with formalin-, capsaicin-, carrageenan- and CFA-induced inflammatory pain
PopulationNot reported
DesignControlled animal experiment
Sample size as reportedNot reported
Control groupvehicle-treated mice with induced inflammatory pain
Route (data field only)other
Endpoints measuredmechanical allodynia; nocifensive behaviour; spinal inflammatory factors; glial and neuronal activation; CGRP and P2X3 nociceptive neuron activity
Pathways measuredInflammation
Research areasNervous system · Inflammation & immunity
Evidence tierC — Animal in vivo
Publication typesJournal Article

Appraisal

Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.

Relevance to MOTS-c
Direct
Model applicability
Mammalian
Sample size
Not reported
Controls
Appropriate
Outcome validity
Surrogate
Support for its own conclusion
Moderate

Provenance

  • Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
  • Annotated from the published abstract.
  • Editorial review: approved (2026-11-11).
  • Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.